Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human colorectal, pancreatic and hepatic carcinoma cell lines

Publication from the Dr. Rath Research Institute

Authors

M. Waheed Roomi, Ph.D.
Senior Researcher
Biochemical Toxicology

T. Kalinovski, M.S., R.N., MHSA
Researcher
Microbiology/Immunology

A. Niedzwiecki, Ph.D.
CEO Dr. Rath Research Institute
Biochemistry

M. Rath, M.D.
Founder of Dr. Rath Research Institute
Founder of the scientific concept of Cellular Medicine
What Are Gastrointestinal (GI) Cancers

- Group of cancers that affect the digestive system

- Includes the following cancers:
  - Esophagus
  - Gallbladder
  - Liver
  - Pancreas
  - Stomach
  - Small intestine
  - Bowel (large intestine or colon and rectum)
  - Anus
1. Colorectal cancer
2. Pancreatic cancer
3. Liver cancer
Colorectum is a part of our GI tract

**COLON**
- Absorbs water, minerals, nutrients
- Nutrients mix with mucus and bacteria in the intestine, starting the formation of feces
- Bacteria break down the fiber to produce nutrients that nourish the cells that line the colon
- The residue (feces) is transferred to the rectum and anus by peristaltic movements

**RECTUM**
- Final part of the digestive tract, opens into the anal canal
- Temporary storage of feces/waste material
- Accumulated feces put pressure on the rectum walls, initiating defecation reflux and their movement to the anal canal
The third most commonly diagnosed cancer and the third leading cause of cancer death (US, 2014).

Very treatable when detected early but once the cancer metastasizes to lymph nodes, liver or other areas, the 5-year survival rate is < 10%.
Symptoms:
- Change in bowel habits including diarrhea or constipation
- Rectal bleeding or blood in the stool
- Persistent abdominal discomfort, cramps, gas or pain
- Weakness or fatigue
- Unexplained weight loss

Most colorectal cancers start as a polyp, a small noncancerous clump of cells that develops at the inner wall of the colon or rectum. Over time, some of these polyps become colon cancers.
An abdominal organ, located behind the stomach

Functions

- **Exocrine:**
  Produces digestive enzymes that break down proteins, fats and carbohydrates. It assists in the absorption of nutrients by the intestines.

- **Endocrine:**
  Produces hormones such as insulin. Maintains healthy blood glucose and salt levels.

**Consequences of pancreas dysfunction:** problems with digesting food or maintaining the blood sugar within a healthy range.

- Diarrhea, bloating, flatulence
- Weight loss, malnutrition
- Poor blood sugar control, diabetes
• Aggressive, spreads rapidly
• Poor prognosis, even if diagnosed early
• Symptoms: abdominal pain, weight loss, diarrhea, jaundice
• Symptoms may not appear until the cancer is advanced and surgical removal is impossible
LIVER

Largest internal organ, located on the right side of the belly, above the stomach

**Functions:**

- Detoxifies the blood
- Produces bile needed for the digestion of fats
- Stores some vitamins and iron
- Controls blood levels of amino acids, fats and glucose
- Breaks down food and turns it into energy
- Manufactures, breaks down and regulates hormones, including sexual hormones
- Produces enzymes and proteins, responsible for most chemical reactions in the body such as blood clotting and repair of damaged tissues
Primary liver cancer:
Accounts for 2% of cancers in the US, but almost 50% of all cancers in some undeveloped countries (mainly attributable to the high prevalence of hepatitis that predisposes to liver cancer)

Symptoms:
- Significant weight loss (> 10% of body weight)
- Swelling of abdomen
- Jaundice
- Itching
- Feeling full after eating, even after a small meal

Risk factors:
- Genetic or hereditary
- Alcohol abuse
- Chronic infection (hepatitis)
- Inherited diseases
Cancer cells (CC) use collagen digesting enzymes to invade nearby tissue.

Angiogenesis

Micrometastases stimulate the growth of new blood vessels to obtain a blood supply needed to obtain the oxygen and nutrients necessary for continued growth of a new metastatic tumor. Process involves enzymatic destruction and restructuring of collagen.

Intravasation

CC use collagen digesting enzymes to pass through blood vessel walls and enter the lymphatic system.

Proliferation

CC established in a new tissue multiply to form small tumors (micrometastases).

Circulation

CC move in the body through the lymphatic system and bloodstream.

Arrest and extravasation

CC in small blood vessels (capillaries) in another organ cross the vascular wall barrier and migrate into the surrounding tissue (extravasation) with the help of collagen digesting enzymes.

Key steps in cancer invasion and metastasis:

1. Local invasion
2. Intravasation
3. Circulation
4. Arrest and extravasation
5. Proliferation
6. Angiogenesis
Cells of our body are embedded in a network of collagen and other connective tissue molecules (extracellular matrix) which keep them in place.

In order to migrate through the connective tissue, a cell has to break down a dense network of connective tissue.

Cells secrete enzymes that break down the extracellular matrix dissolving the surrounding tissue (collagen and elastin fibers).
METASTASIS

CELLULAR MIGRATION AND EXTRACELLULAR MATRIX

HOW CANCER CELLS INVADE OTHER ORGANS
(METASTASIS)

✓ The collagen-dissolving mechanism is essential in tumor invasion and cancer cell migration.

✓ Every tumor contains a network of small blood vessels (capillaries). With the help of collagen-dissolving enzymes, cancer cells break through the blood vessel wall and enter the blood stream.

✓ Once in the blood stream, the cancer cells move to other organs/parts of the body via the blood flow.

✓ Cancer cells leave the blood stream using collagen-digesting enzymes to form metastatic (secondary) tumors.

Tumor invasion depends on integrity of the extracellular matrix (ECM), which, when intact, acts as a barrier to block cancer cell invasion.
There are several types of enzymes that cancer cells use to digest connective tissue including:

- Urokinase also called Urokinase-type Plasminogen Activator (uPA)
- Matrix Metalloproteinases (MMPs)

The more collagen digesting enzymes a cancer cell produces, the more aggressive the cancer is and the faster it spreads through the body.
TUMOR INVASION AND METASTASIS

MATRIX METALLOPROTEINASES (MMPs)

- A family of enzymes responsible for the breakdown of connective tissue proteins
- Excessive MMPs expression, especially MMP-2 and MMP-9, plays a key role in tumor cell invasion and metastasis
- Clinical studies document the association of the MMPs expression with progression of colon, pancreatic and hepatic cancer
- MMPs expression has been associated with stage IV tumors showing the highest MMPs levels
Tissue inhibitors of metalloproteinases (TIMPs):
Multifunctional proteins that inhibit activities of MMPs
They play a role in tumor growth and metastasis
Components of the uPA system are overexpressed in a variety of cancer types, including colon and pancreatic cancer.

- uPA converts plasminogen to plasmin, which is capable of:
  - Promoting tumor growth and angiogenesis
  - Degrading the ECM
  - Activating pro MMPs

- High levels of uPA correlate with cancer progression, metastasis and poor patient prognosis.

New approach tested in our study

New approach to a natural control of cancer presented by M. Rath and L. Pauling in 1992

This publication proposes new universal approach to halting the spread and metastasis of cancer. Its main focus is on preserving extracellular matrix integrity by controlling its proteolysis (MMPs and uPA) and at the same time optimizing its synthesis.

Plasmin-Induced Proteolysis and the Role of Apoprotein(a), Lysine, and Synthetic Lysine Analogs

M. Rath, L. Pauling

Study objective

Investigate the effect of a nutrient mixture containing natural inhibitors of ECM digestion and activators of its production on the activities of uPA, MMP-2, MMP-9 and TIMPs in human colon, pancreatic and hepatic carcinoma cell lines.

Earlier studies with this nutrient mixture have shown its effectiveness in inhibiting metastasis and MMPs activity in various types of cancers.

For earlier studies visit: www.drrathresearch.org
The nutrient mixture (NM) was composed of the following ingredients in the relative amounts indicated:

- Vitamin C (as ascorbic acid, Mg and Ca ascorbates and ascorbyl palmitate), 700 mg
- L-lysine, 1000 mg
- L-proline, 750 mg
- L-arginine, 500 mg
- N-acetyl cysteine, 200 mg
- Standardized green tea extract (80% polyphenols), 1000 mg
- Selenium, 30μg
- Copper, 2 mg
- Manganese, 1 mg
In Vitro tests

Human colon, pancreatic and liver (hepatocellular carcinoma) cancer cell lines were grown in tissue culture media.

Cells were treated in triplicate with different concentrations of the nutrient mixture:

- For uPA and TIMP activity tests cells were treated with NM at 0, 50, 100, 250, 500, 1000 μg/ml
- For MMP analysis cells were treated with NM at 0, 10, 50, 100, 500, 1000 μg/ml
• The effects of NM on the following enzymatic activities in human colorectal, pancreatic and liver cancer cells

1. uPA activity
2. MMP-2 and MMP-9 secretion
3. TIMP activity

• Correlation between uPA, TIMP-2 and MMP expression levels
NM inhibits uPA activity in human colorectal, pancreatic and liver carcinoma cell lines.

u-PA consists of two subunits, joined by a S-S-disulphide bridge:
- Subunit 1 (35KDa)
- Subunit 2 (33 Kda)

NM inhibited uPA activity in colorectal, pancreatic and liver carcinoma in a dose-dependent manner.
Colon cancer cell line (HCT-116) does not express MMP2. These cancer cells produce MMP-9, which was inhibited by NM in a dose-dependent manner with total (100%) inhibition of MMP-9 at 100 μg/ml.
Pancreatic cancer cell line (MIA PaCa-2)

- These cancer cells do not secrete MMP-2
- These cancer cells secrete MMP-9, which is enhanced by the exposure to PMA (phorbol 12-myristate 13-acetate)
- NM inhibited MMP-9 secretion by untreated pancreatic cancer cells at 1000 μg/ml and also PMA-treated cells at 1000 μg/ml

PMA = a potent tumor promotor and inducer of MMPs
Liver cancer cell line (HCC cell line SK-Hep-1)

- These cells secrete MMP-9 and MMP-2 enzymes without and with PMA stimulation.
- NM inhibits the secretion of these enzymes in a dose-dependent manner with total inhibition of MMP-9 at 1000 μg/ml and MMP-2 at 500 μg/ml. In PMA-treated cells the MMP-9 and MMP-2 secretion was 100% inhibited at these concentrations, respectively.
NM stimulates TIMP-2 activity in colon, pancreatic and liver cancer cells

TIMP-2 activity increased in all cancer cell lines after exposure to NM in a dose-dependent manner. Minimum TIMP-2 activity was expressed at NM of 50 ug/ml (colon cancer) and maximum at 1000 μg/ml NM all tested cancer cells.
We evaluated whether activity of uPA, MMPs and TIMP-2 in all tested cells exposed to different NM concentrations have some relation to each other by calculating their correlation coefficients.

- A positive correlation was found between uPA and MMP-9 expression levels of NM treated colon, pancreatic and liver carcinoma, which means that NM was effective in simultaneously inhibiting MMP-9 and uPA in these cancer cell types.
- Negative correlations were found between the expression of MMP-9 and TIMP-2 in all three cancer cell lines treated with NM. This means that stimulation of TIMP-2 by the exposure of cells to NM was accompanied by a decrease in MMP-9 activity.
- Negative correlations were found between expression levels of TIMP-2 and uPA in all three cell lines treated with NM which means that stimulation of TIMP-2 by the exposure of cells to NM was accompanied by a decrease in uPA activity.

Inhibition of uPA and MMPs by NM correlates with higher expression of TIMP-2 in colon, pancreatic and liver cancer cell lines.
SUMMARY OF THE RESULTS

1. Exposure of gastrointestinal cancer cells to the specific mixture of nutrients containing natural inhibitors of extracellular matrix proteolysis resulted in:
   • Inhibition of uPA secretion in colon, pancreatic and liver cell lines
   • Decrease in MMP9 and MMP2 secretions
   • Increase in TIMP-2 secretion by all these cell lines.

2. A positive correlation was found between the secretion of uPA and MMP-9.

3. A negative correlation was found between uPA and TIMP-2 and between MMP-2 and TIMP-2 secretion by NM treatment of colon, pancreatic and liver cancer cell lines.
IMPLICATIONS OF THESE FINDINGS

The nutrient mixture tested in this study demonstrated a potent anticancer activity by targeting important mechanisms responsible for aggressive spread and metastasis of colon, pancreas and liver cancers, which is enzymatic degradation of extracellular matrix.

This nutrient mixture does not have toxic effects.

Hence, dietary intake of the mixture of phytonutrients should be considered in developing safe and effective approaches to effective control GI cancers.